B Cell-Based Vaccine Transduced With ESAT6-Expressing Vaccinia Virus and Presenting α-Galactosylceramide Is a Novel Vaccine Candidate Against ESAT6-Expressing Mycobacterial Diseases

B Cell-Based Vaccine Transduced With ESAT6-Expressing Vaccinia Virus and Presenting α-Galactosylceramide Is a Novel Vaccine Candidate Against ESAT6-Expressing Mycobacterial Diseases

Early secretory antigenic target-6 (ESAT6) is a potent immunogenic antigen expressed in Mycobacterium tuberculosis as well as in some non-tuberculous mycobacteria (NTM), such as M. kansasii. M. kansasii is one of the most clinically relevant species of NTM that causes mycobacterial lung disease, whi...

Full description

Bibliographic Details
Main Authors: Bo-Eun Kwon, Jae-Hee Ahn, Eun-Kyoung Park, Hyunjin Jeong, Hyo-Ji Lee, Yu-Jin Jung, Sung Jae Shin, Hye-Sook Jeong, Jung Sik Yoo, EunKyoung Shin, Sang-Gu Yeo, Sun-Young Chang, Hyun-Jeong Ko
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-10-01
Series:Frontiers in Immunology
Subjects:
Mycobacterium kansasii
Mycobacterium tuberculosis
non-tuberculous mycobacteria
ESAT6
vaccine
α-galactosylceramide
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2019.02542/full

Internet

https://www.frontiersin.org/article/10.3389/fimmu.2019.02542/full

Similar Items